Home

Neurocrine Biosciences, Inc. - Common Stock (NBIX)

131.24
-3.89 (-2.88%)
NASDAQ · Last Trade: Jul 16th, 12:29 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunityinvestors.com
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via Investor's Business Daily · July 10, 2025
A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analystsbenzinga.com
Via Benzinga · July 9, 2025
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuationchartmill.com
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks in the biotech sector.
Via Chartmill · July 9, 2025
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potentialchartmill.com
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch. High profitability, no debt, and a potential breakout add to its appeal.
Via Chartmill · July 4, 2025
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Via MarketBeat · June 29, 2025
Analyst Expectations For Neurocrine Biosciences's Futurebenzinga.com
Via Benzinga · June 2, 2025
Earnings Scheduled For May 5, 2025benzinga.com
Via Benzinga · May 5, 2025
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Promising Affordable Growth Stockchartmill.com
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth in the biotech sector.
Via Chartmill · June 18, 2025
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potentialchartmill.com
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth, profitability, and a bullish technical setup, making it a stock worth watching for growth investors.
Via Chartmill · June 12, 2025
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuationchartmill.com
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it a candidate for investors seeking affordable growth stocks in the biotech sector.
Via Chartmill · May 28, 2025
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potentialchartmill.com
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a promising technical setup, making it a stock to watch for potential breakout opportunities.
Via Chartmill · May 21, 2025
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Targetbenzinga.com
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.
Via Benzinga · May 6, 2025
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Druginvestors.com
The company reported a strong start for its newest drug, Crenessity, which treats a hormonal disorder involving the adrenal glands.
Via Investor's Business Daily · May 6, 2025
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · May 6, 2025
What 19 Analyst Ratings Have To Say About Neurocrine Biosciencesbenzinga.com
Via Benzinga · May 6, 2025
Neurocrine Biosciences Stock Surges After-Hours On Upbeat Q1, Reaffirmed Ingrezza Outlook — Retail Buzz Soarsstocktwits.com
CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth.
Via Stocktwits · May 5, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · May 5, 2025
Top movers in Monday's after hours sessionchartmill.com
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · May 5, 2025
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is not too expensive for the growth it is showing.chartmill.com
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · May 5, 2025
What to Expect from Neurocrine Biosciences's Earningsbenzinga.com
Via Benzinga · May 2, 2025
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stockchartmill.com
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock
Via Chartmill · May 1, 2025
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?benzinga.com
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
Via Benzinga · April 20, 2025
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullishbenzinga.com
Physician survey shows high uptake of Neurocrine Biosciences' Crenessity for patients with CAH.
Via Benzinga · April 15, 2025
What 16 Analyst Ratings Have To Say About Neurocrine Biosciencesbenzinga.com
Via Benzinga · April 15, 2025
This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesdaybenzinga.com
Via Benzinga · April 15, 2025